Characterization of omalizumab updosing patterns and predictive factors in chronic spontaneous urticaria: A prospective multicentric observational study
Allergy · 2024
DOI: 10.1111/all.16256 ↗At a glance
Multizentrische Studie in Allergy, 2024. Written by Guillaume Pierrard and 11 co-authors. Institution: CHU Lille, University Lille, Service de Dermatologie, Lille, France. Major MEDLINE topics: Omalizumab, Chronic Urticaria, Anti-Allergic Agents. Cited 10 times so far (Crossref); 39 references. The full text is freely available (open access, CC BY-NC 4.0).
Abstract (original language)
Background
Limited information is available on the use of omalizumab (OMA) updosing since its introduction as a second‐line therapy in chronic spontaneous urticaria (CSU) in 2014. Practical guidelines from health authorities are lacking, and the specific characteristics of patients requiring higher doses remain unknown. Our objectives were to characterize the patterns of OMA updosing (defined as changes in dose and/or injection intervals), to identify the predictive factors associated with updosing, and to improve CSU management.
Methods
We conducted a prospective, multicentric, real‐life observational study, including patients diagnosed with CSU and starting OMA. The data were collected at 0, 3, 6, and 9 months. The primary endpoint was the frequency of OMA updosing at 3 months. The secondary endpoints included an analysis of updosed patients' profile, and an assessment of OMA efficacy and safety.
Results
We included 153 patients. Twenty percent of patients were updosed at 3 months, and 27% in total during the 9‐month follow‐up. Practitioners mainly chose to increase the frequency of injections (66%). At baseline, the updosed patients were more likely to have more severe CSU (UCT < 4, p < 0.030), a lower lymphocyte count (
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- CHU Lille, University Lille, Service de Dermatologie, Lille, France.
- French Chronic Urticaria Study Group (GUS), Paris, France.
- CHU Nantes, Service de Dermatologie, Nantes, France.
- CHU Montpellier, Service de Dermatologie, Montpellier, France.
- CHU Le Mans, Service de Dermatologie, Le Mans, France.
- Sorbonne Université, Service de Dermatologie et d'Allergologie, Hôpital Tenon, Paris, France.
ORCID profiles: Guillaume Pierrard, Angèle Soria, Frédéric Dezoteux
Cite
APA
Pierrard, G., Bernier, C., Du-Thanh, A., Bara, C., Soria, A., Castelain, F., Boccon-Gibod, I., Hacard, F., Delaunay, J., de Montjoye, L., Staumont-Salle, D., & Dezoteux, F. (2024). Characterization of omalizumab updosing patterns and predictive factors in chronic spontaneous urticaria: A prospective multicentric observational study. Allergy. https://doi.org/10.1111/all.16256
Vancouver
Pierrard G, Bernier C, Du-Thanh A, Bara C, Soria A, Castelain F, et al. Characterization of omalizumab updosing patterns and predictive factors in chronic spontaneous urticaria: A prospective multicentric observational study. Allergy. 2024. doi:10.1111/all.16256
BibTeX
@article{Pierrard2024,
author = {Pierrard, Guillaume and Bernier, Claire and Du-Thanh, Aurélie and Bara, Corina and Soria, Angèle and Castelain, Florence and Boccon-Gibod, Isabelle and Hacard, Florence and Delaunay, Juliette and de Montjoye, Laurence and Staumont-Salle, Delphine and Dezoteux, Frédéric},
title = {Characterization of omalizumab updosing patterns and predictive factors in chronic spontaneous urticaria: A prospective multicentric observational study},
journal = {Allergy},
year = {2024},
doi = {10.1111/all.16256}
}
EUVIMED